Registration Dossier

Data platform availability banner - registered substances factsheets

Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.

The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.

Diss Factsheets

Administrative data

Description of key information

Candesartan is suspected to cause maldevelopment in fetuses and neonates born to mothers treated with the substance during pregnancy. 
The target organs are bons (ossification abnormalities) and kidney (renal failure).
Angiotensin II receptor antagonists should not be used beyond the first trimester of pregnancy.

Additional information